Scientists closer to developing artificial livers

Image
Press Trust of India Washington
Last Updated : Jun 03 2013 | 2:12 PM IST
MIT researchers, including an Indian origin scientist, have made a breakthrough that may lead to development of artificial livers for transplantation.
Scientists trying to exploit the ability of liver to grow in hopes of producing artificial liver tissue for transplantation have repeatedly been stymied.
Mature liver cells, known as hepatocytes, quickly lose their normal function when removed from the body.
According to Massachusetts Institute of Technology (MIT) engineer Sangeeta Bhatia the liver can indeed regenerate itself if part of it is removed.
"It's a paradox because we know liver cells are capable of growing, but somehow we can't get them to grow" outside the body, said Bhatia.
Bhatia and colleagues have identified a dozen chemical compounds that can help liver cells not only maintain their normal function while grown in a lab dish, but also multiply to produce new tissue.
Cells grown this way could help researchers develop engineered tissue to treat many of the 500 million people suffering from chronic liver diseases such as hepatitis C, according to the researchers.
Researchers adapted the system so that the liver cells could grow, in layers with the fibroblast cells, in small depressions in a lab dish. This allowed the researchers to perform large-scale, rapid studies of how 12,500 different chemicals affect liver-cell growth and function.
Researchers measured expression levels of 83 liver enzymes representing some of the most finicky functions to maintain.
After screening thousands of liver cells from eight different tissue donors, they identified 12 compounds that helped the cells maintain those functions, promoted liver cell division, or both.
Two of those compounds seemed to work especially well in cells from younger donors, so the researchers also tested them in liver cells generated from induced pluripotent stem cells (iPSCs).
Scientists have tried to create hepatocytes from iPSCs before, but such cells don't usually reach a fully mature state. However, when treated with those two compounds, the cells matured more completely.
In future studies, the MIT team plans to embed the treated liver cells on polymer tissue scaffolds and implant them in mice, to test whether they could be used as replacement liver tissues. They are also pursuing the possibility of developing the compounds as drugs to help regenerate patients' own liver tissues.
Bhatia and colleagues have also recently made progress toward solving another challenge of engineering liver tissue, which is getting the recipient's body to grow blood vessels to supply the new tissue with oxygen and nutrients.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 03 2013 | 2:12 PM IST

Next Story